TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild-moderate chronic kidney disease (glomerular filtration rate \[GFR\] 40-80 mls/min calculated by Cockroft-Gault equation)~* Controlled blood pressure (\< 130/80 mmHg)~* On established (\> 6 weeks) treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).~Exclusion Criteria:~* Diabetes mellitus~* Clinical evidence of fluid overload or hypovolaemia~* Recent (\< 2 months) acute myocardial infarction~* Left ventricular (LV) dysfunction (ejection fraction \< 40% by echocardiography).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone (Type: ACTIVE_COMPARATOR): 25mg spironolactone daily
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo medication for the control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed unresectable stage IV melanoma~* Measurable metastatic disease~* No uncontrolled brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 70-100%~Life expectancy:~* More than 12 weeks~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* SGOT and SGPT no greater than 3 times ULN~* Alkaline phosphatase no greater than 3 times ULN~Renal:~* BUN no greater than 1.5 times ULN~* Creatinine no greater than 1.5 times ULN~Cardiovascular:~* No significant cardiovascular disease~Other:~* No non-malignant systemic disease~* No acute infection requiring IV antibiotics~* No alcohol or substance abuse~* No other condition, disease, or history of other illness that would preclude study participation~* No hypersensitivity, allergic reactions, or intolerance to study drugs~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy~* No prior interleukin-2~* No other concurrent immunotherapy~* No concurrent investigational vaccines or immunomodulatory agents~* No other concurrent growth factors~Chemotherapy:~* At least 4 weeks since prior chemotherapy~* No prior temozolomide~* No other concurrent anticancer chemotherapy~Endocrine therapy:~* No concurrent steroids (including corticosteroids)~Radiotherapy:~* At least 4 weeks since prior radiotherapy~Surgery:~* See Disease Characteristics~* At least 3 weeks since prior major surgery~Other:~* At least 30 days since prior immune-based therapy~* No concurrent participation in other clinical trials with investigational drugs~* No other concurrent anticancer drugs~* No concurrent immunosuppressive therapy~* No concurrent levamisole or cimetidine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CANVAS - CANagliflozin cardioVascular Assessment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of type 2 diabetes mellitus and greater than or equal to (\>=) 30 yrs old with history of cardiovascular (CV) event, or \>= 50 yrs old with high risk of CV events~* Patients must have inadequate diabetes control (as defined by glycosylated hemoglobin greater than or equal to 7.0% to less than or equal to 10.5% at screening) and be either (1) not currently on diabetes drug therapy or (2) on therapy with any approved class of diabetes drugs~Exclusion Criteria:~* A history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* History of one or more severe hypoglycemic (ie, very low blood sugar) episode within 6 months before screening

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive placebo (inactive medication) on background standard of care for diabetes once daily for the duration of the study
- Canagliflozin (JNJ-28431754) 100 mg (Type: EXPERIMENTAL): Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily on background standard of care for diabetes once daily for the duration of the study
- Canagliflozin (JNJ-28431754) 300 mg (Type: EXPERIMENTAL): Each patient will receive canagliflozin (JNJ-28431754) 300 mg once daily on background standard of care for diabetes once daily for the duration of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Plasma triglycerides (TG) at Screening greater than (\>)150 milligrams per deciliter (mg/dL) and at qualification of \>150 mg/dL.~* Documented history of hepatic steatosis with baseline magnetic resonance imaging (MRI) indicating hepatic fat fraction (HFF) greater than (\>) 8%.~* Diagnosis of Type 2 diabetes mellitus with hemoglobin A1c (HbA1c) \>6.5 and less than or equal to (≤) 10% at Screening.~* Must have been on a stable dose of oral antidiabetic therapy for a minimum of 3 months prior to Screening.~* Body mass index between 27- 40 kilograms per meter square (kg/m\^2), inclusive, at Screening.~Key Exclusion Criteria:~* Type 1 diabetes mellitus.~* Active chronic liver disease, alcoholic liver disease, Wilson's disease hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, genetic hemochromatosis, known or suspected hepatocellular carcinoma, history of or planned liver transplant for end-stage liver disease of any etiology.~* Documented history of advanced liver fibrosis.~* History of cirrhosis and/or hepatic decompensation including ascites, hepatic encephalopathy, or variceal bleeding.~* History of clinically significant acute cardiac event within 6 months before Screening.~* History of heart failure with New York Heart Association (NYHA) greater than Class II.~* Use of Insulin or insulin analogs, glucagon-like peptide-1 (GLP-1) agonists, and peroxisome proliferator-activated receptor gamma (PPARᵞ) agonists (pioglitazone or rosiglitazone).~* Weight change \>5% within 3 months before Screening.~* Conditions contraindicated for magnetic resonance imaging (MRI) procedures including any metal implant (example, heart pacemaker, rods, screws, aneurysm clips).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pooled Placebo (Type: PLACEBO_COMPARATOR): Participants from each cohort received placebo at a dose-matched volume of study drug, subcutaneously (SC).
- Cohort B: ISIS 703802, 40 mg Q4W (Type: EXPERIMENTAL): Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.
- Cohort C: ISIS 703802, 80 mg Q4W (Type: EXPERIMENTAL): Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.
- Cohort A: ISIS 703802, 20 mg QW (Type: EXPERIMENTAL): Participants received ISIS 703802, 20 mg once every week for 26 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amlodipine as add-on to Olmesartan in Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Mean sitting BP of greater than or equal to 140/90-115 mmHg and mean 24h dBP greater than or equal to 80 mmHg with at least 30% of daytime readings greater than 85 mmHg prior to randomization.~Exclusion Criteria:~* Secondary hypertension of any aetiology;~* Any serious disorders which may limit the ability to evaluate the efficacy or safety of the test drug(s);~* History of myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, congestive heart failure, hypertensive encephalopathy, stroke or TIA within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of COPD (according to GOLD guidelines)~* FEV1 \> or equal 30% and \< 50% of predicted normal post-bronchodilator (and at least 0.7 L absolute value)~* COPD symptoms for at least 2 years~* At least 1 exacerbation requiring medical intervention (oral corticosteroid and/or antibiotic treatment and/or need for a visit to an emergency department and/or hospitalization) within 2-12 months before screening~* Current or previous smoker with a cumulative exposure to smoke of more than 20-pack year~Exclusion Criteria:~* Current or past diagnosis of asthma, or any evidence suggestive of asthma~* Positive FEV1 reversibility test~* Clinically significant or unstable concurrent diseases, including clinically significant laboratory abnormalities~* Acute COPD exacerbation or lower tract infection and/or treatment with oral or injectable corticosteroids and antibiotics in the 2 months before screening or during run-in~* Long term oxygen therapy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI (Type: EXPERIMENTAL): None
- Budesonide 200 µg plus formoterol 6 µg DPI (Type: ACTIVE_COMPARATOR): None
- Formoterol 12 µg DPI (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Not currently on drug therapy for type 2 diabetes~* Blood glucose criteria must be met~* Body mass index (BMI) in the range 22-45~Exclusion Criteria:~* History of type 1 diabetes~* Evidence of significant diabetic complications~* Serious cardiovascular events within the past 6 months~* Laboratory value abnormalities as defined by the protocol~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Can A Prescribed Walking Program With or Without Monitoring Impact Dizziness in the Older Adults?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 65 years or older referred for physical therapy evaluation for symptoms of dizziness, postural instability, or both~2. Able to walk without the physical help of another person, with or with no assistive device~3. Able to follow commands and execute the examination and intervention instructions in the English language~4. Willing to participate in a phone interview four weeks after discharge~5. Able to provide informed consent~Exclusion Criteria:~1. Unstable medical issues, such as unstable or uncontrolled cardiovascular conditions, elevated blood pressure (Systolic greater than or equal to 140mmHg and diastolic greater than or equal to 90mmHg), orthostatic hypotension (a fall in systolic blood pressure of at least 20mmHg or diastolic blood pressure of at least 10mmHg when a person stands from a sitting or lying down position), uncontrolled metabolic disease, as determined by the evaluating physical therapist, documented in the Functional Comorbidity Index, vital signs and assessment portion of the initial evaluation.~2. History of falls from syncopal origin~3. Dizziness of central origin, such as stroke, head injuries, MS or PD;~4. Active BPPV (patients with positive dix hallpike and/or roll test)~5. Inability to walk without physical assistance.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VRWP Group (Type: EXPERIMENTAL): Vestibular Rehabilitation plus Walking with Pedometer Groupd
- VRW Group (Type: ACTIVE_COMPARATOR): Vestibular Rehabilitation plus Walking without Pedometer Group
- VR Group (Type: NO_INTERVENTION): Vestibular Rehabilitation Only Group. The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* •Adult female-16 years to 35 years of age who have been diagnosed with PCOS desiring contraception~  * Actual BMI \>18 to \<35kg/ m2~ * Written consent for participation in the study~ * Patient completed lactation~Exclusion Criteria:~* Metabolic abnormalities requiring pharmacological intervention (except controlled thyroid disease)~  * Uncontrolled hypertension~ * Cancer or history of hormone-dependent cancer~ * History of cholestasis~ * Presence of contradictions for OC administration~ * Personal history of cardiovascular events.~ * Use of drugs known to exacerbate glucose tolerance.~ * No prescription or over-the-counter weight-loss drugs~ * Diabetes~ * Use of medications that affect blood pressure or lipid profile~ * Smoking in past 6 months~ * Known thrombogenic mutations (e.g. Factor V Leiden)~ * Current or history of deep venous thrombosis/pulmonary embolism~ * Major surgery with prolonged immobilization~ * Injectable hormonal contraceptive use within 6 months~ * Use of hormonal (e.g., oral contraceptive \[OC\] pill) or insulin-sensitizing medication unless willing to cease medications for 3 months before study measurements

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- 3 mg DRSP/20 μg EE--normal weight (Type: EXPERIMENTAL): Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~Normal weight -BMI 18-24.9 kg/ m2
- 3 mg DRSP/20 μg EE- Overweight (Type: EXPERIMENTAL): Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 25-29.9 kg/ m2
- 3 mg DRSP/20 μg EE- Grade 1 obese (Type: EXPERIMENTAL): Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 30-34.9 kg/ m2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject is willing and able to participate and provides written informed consent;~2. Healthy subjects with no concomitant medical conditions;~3. Age ≥ 18 years;~4. The subject is willing to take HCT 25 mg a day although not clinically indicated;~5. The subject is willing to undergo controlled UV-exposition although not clinically indicated;~6. Skin type I - IV.~Exclusion Criteria:~1. History of any cardiac disease;~2. History of any dermatologic disease;~3. Renal insufficiency (eGFR \<60 ml/min/1.73m²);~4. Intake of photosensitive substances, especially intake of HCT;~5. Frequent, above-average, UV exposition (naturally or artificially);~6. Known hypertension;~7. Known electrolyte disbalance;~8. Systolic blood pressure at baseline \<100 mmHg;~9. Skin type V and VI;~10. History of severe diseases, which could endanger the safety of study participant;~11. Known unresolved history of alcohol dependency or drug abuse or any other kind of dependencies~12. Intake of any of the following medications or substances: Betablockers; nitrates; barbiturates; phenothiazines; tricyclic antidepressants; vasodilatory drugs; ACE-inhibitors; NSAIDs; salicylates; phenytoin; Insulin; oral antidiabetic drugs; vasoconstrictors; glycosides; substances lowering blood-urea levels; substances causing a Long-QT-Syndrome; chinidine; carbamazepine; cyclosporine; cholecalciferol; potassium salts; amantadine; allopurinol; methyldopa; cholestyramine; colestipol; other diuretics; lithium; cytostatic drugs;~13. Women in childbearing age and not using medically acceptable effective contraception refer to CTFG: The study population includes female of childbearing potential. Female of childbearing potential have to agree to comply with the applicable contraceptive requirements of the protocol for the duration of the study or having post-menopausal status or be permanently sterilized (at least 6 weeks post-sterilization). Highly effective contraception is defined as a contraceptive method with failure rate of less than 1 % per year when used consistently and correctly and when applicable, in accordance with the product label;~14. Subject is pregnant (e.g., positive ß-hCG test) or is breast feeding;~15. Hypersensitivity to the active substance, to HCT or any of its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Intake of HCT 25 mg, 1 tablet/d for 15 days
- Placebo (Type: PLACEBO_COMPARATOR): Intake of Placebo, 1 tablet/d for 15 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fabrazyme in Pediatric Patients With Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patient or legal guardian must provide written informed consent~* Patients must have a clinical diagnosis of Fabry disease and active Fabry disease (clinical signs and symptoms)~* Patients must be at least 7 years of age but no older than 15 years of age at time of enrollment~* Patients must be Tanner Stage ≤ III~* Female patients must have a negative pregnancy test prior to each infusion and use a medically accepted form of contraception throughout the study~Exclusion Criteria:~* Patient has a clinically significant organic disease (with the exception of symptoms relating to Fabry disease) that in the opinion of the investigator would preclude participation in the trial~* Patient has participated in a study employing investigational drug within 30 days of the start of this study~* Patient has received prior treatment with enzyme replacement therapy~* Patient is unable to comply with the clinical protocol

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Fabrazyme (Type: EXPERIMENTAL): 1.0 mg/kg of Fabrazyme given to the patients every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete